Summer 2026
2026 Electrochemical Reaction Engineering Intern
PhD
Posted on 1/23/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
No salary listed
Waukegan, IL, USA
In Person
 Process Engineering |
|---|
- Currently enrolled in university, pursuing a PhD in Chemical Engineering, Chemistry, or other related field
- Must be enrolled in university for at least one semester following the internship
- The candidate is required to possess effective oral and written communication skills and be a strong team player.
- Conduct screening and optimization experiments for electrochemical reaction design
- Analyze data to determine optimal reaction configuration
- Investigate reaction transferability and optimal conditions between small molecules and biologics
- Builds strong relationships with peers and cross-functionally with partners outside of team to enable higher performance.
- Learns fast, grasps the “essence,” and can change course quickly where indicated
- Communicate cross-functionally with chemists and chemical engineers to understand and impact key project deliverables
- Summarize and present findings at end of program
- Expected graduation date between December 2026 – July 2027
- Strong background in electrochemistry/electrocatalysis
- Experience with laboratory experiments and electrochemical characterization techniques (EIS, CV, CA, etc.) and/or electrochemical reactor design
- Exposure to HPLC or other general process analytical tools
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $15B, up 12.4%, raising FY EPS guidance to $14.08-$14.28.
- Skyrizi secured Ontario and Alberta listings for ulcerative colitis reimbursement.
- $1.45B Kestrel deal advances KRAS inhibitor for oncology pipeline expansion.
What critics are saying
- Oruka's ORKA-001 outperforms Skyrizi in psoriasis trials, eroding $17.6B revenue.
- FDA rejected trenibotulinumtoxinE over manufacturing, delaying aesthetics launch.
- ABBV-295 trails Lilly's eloralintide by 2-3 years in $130B obesity market.
What makes AbbVie unique
- AbbVie spun off from Abbott in 2013, focusing R&D on immunology, oncology, neuroscience.
- Skyrizi generated $17.6B in 2025, capturing 45% US biologic psoriasis market share.
- 250+ external innovation partners accelerate AbbVie's transformational medicine pipeline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Company News
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m. April 13, 2026 A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications. Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed. Deal context. The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco is known to be pursuing fast-follower NaV1.8 programs - targeting a voltage-gated sodium channel expressed in peripheral sensory neurons that plays a key role in pain signal transmission - following the approval of Vertex Pharmaceuticals' suzetrigine (Journavx) in January 2025. The Chinese firm has secured patents describing VX-548-derived scaffolds incorporating bioisosteric substitutions to modify the core structure. AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson's, and epilepsy. The deal also represents the latest collaboration between AbbVie with China-based partners. In January 2026, AbbVie struck a deal worth in excess of USD 5 billion with Remegen for a PD-1/VEGF bispecific antibody, while two separate partnerships were signed in 2025, with Zelgen Biopharmaceuticals for T-cell engagers, and Simcere Pharma for a trispecific antibody. For Haisco, the deal represents an extension of an international out-licensing strategy the company has pursued since 2015. Other notable partners include US based biotech AirNexis, which signed a deal worth in excess of USD 1 billion in January 2026 for PDE/4 respiratory asset of Haisco, HSK39004 The Chengdu-based company has R&D operations in Shanghai and Silicon Valley and has previously pursued international expansion through out-licensing, co-development, and acquisitions. Previous multinational partners include US biotech AirNexis and Italy's Chiesi Farmaceutici SpA. Your email address will not be published. Required fields are marked *
Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development. Monday, Apr 13, 2026 2:26 am ET 1min read Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop novel medicines for pain treatment globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds at various development stages. Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments, plus royalties on future net sales. The collaboration is expected to generate sustainable value and long-term returns. Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop and commercialize two Nav1.8 inhibitors for pain treatment outside of mainland China, Hong Kong, and Macau. The compounds, HSK55718 and HSK51155, are intended for the development of non-opioid analgesics and are at different stages of clinical development. HSK55718 is in Phase I clinical trials in China as an intravenous therapy, while HSK51155 is in the preclinical stage as an oral formulation according to the announcement. Under the terms of the agreement, Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in milestone payments, in addition to royalties on future net sales. AbbVie will also cover certain research and development costs through the proof-of-concept phase. The deal is expected to support Haisco's global expansion and enhance its long-term profitability. The collaboration aligns with Haisco's strategy to advance its innovative drug portfolio and strengthen its international commercialization efforts. Ask Aime: What are the potential impacts of Haisco's licensing deal with AbbVie on its stock performance? Aime insights. What's the performance trend of major Indian companies listed on US stock exchanges? Between Microsoft and Google, which is better for long-term holding? How to evaluate a company's competitive advantage? How does R&D spending compare among semiconductor leaders over years?
AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.
March update: Antibody Industry Trends (Q1 2026 insights, trends & analysis). Apr 10, 2026 Biointron's Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. Gain exclusive insights into current trends such as: * 3 novel antibody drugs approved for the first time in Q1 2026 * Top 20 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8.5B * Trends in early developability for antibody discovery * Current research into multiple myeloma treatments * A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q2 2026 Selected report highlights. This quarter, three novel monoclonal antibody drugs have been approved by China. * Libevitug (华优诺): First approved in China on January 23, 2026. It is a human mAb targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), indicated for chronic hepatitis D virus infection in adults with or without compensated cirrhosis. * Retlirafusp Alfa (艾泽利): First approved in China on January 7, 2026. It is a bispecific fusion protein that targets PD-L1 and TGF-beta, indicated for fully validated PD-L1 positive (CPS>=1), locally advanced, unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma. * Amdokitug (益赛拓): First approved in China on February 13, 2026. It is a recombinant humanized anti-IL17A IgG1κ mAb, indicated for adult patients with moderate-to-severe plaque psoriasis (PsO) eligible for systemic therapy or phototherapy. Q1 2026 saw many acquisitions, collaborations, and licensing agreements for bispecific and trispecific antibody drugs. Significant investment has been directed toward startups targeting a diverse range of therapeutic areas, such as central nervous system (CNS) disorders and inflammatory diseases. Top 5 deals by volume: * Feb 9: Innovent Biologics announces strategic collaboration with Eli Lilly and Company to develop new medicines globally in oncology and immunology, in potential $8.5B deal. * Jan 12: AbbVie and RemeGen Biosciences announce licensing agreement to develop a novel PD-1/VEGF bispecific in potential $5.6B deal. * Jan 5: Earendil Labs announces strategic collaboration with Sanofi to discover bispecific antibodies for autoimmune diseases in up to $2.56B deal. * Jan 20: GSK to acquire RAPT Therapeutics for $2.2B, gaining anti-IgE antibody to protect against food allergy reactions. * Mar 23: Gilead Sciences to acquire Ouro Medicines, gaining OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases, in potential $2.18B deal. Early developability in discovery. Monoclonal antibody discovery has shifted toward larger, faster pipelines driven by automation and computational design. As a result, early developability assessment has become a critical layer in candidate selection, helping identify molecular risks related to stability, manufacturability, and formulation before they emerge in later development stages. Developability refers to the set of molecular attributes that influence whether an antibody can be efficiently manufactured, formulated, and advanced through development. These properties, while not directly related to antigen binding, can strongly impact stability, product consistency, and downstream feasibility. By combining multi-parameter profiling, high-throughput screening, and predictive tools, developability assessment enables earlier identification of risks, more efficient candidate prioritization, and improved alignment between discovery and downstream development. Antibody startup launches/companies to watch. Date: March 20, 2026 | Seed Round: €17 million Laigo Bio is advancing targeted protein degradation therapies. Their SureTACs(TM) platform, which uses bispecific antibodies to selectively eliminate disease-causing membrane proteins. By pairing target proteins with E3 ligases, the approach induces precise ubiquitination and lysosomal degradation, enabling dual-targeted removal of pathogenic proteins. They aim to develop therapies in oncology and autoimmune diseases. Date: January 26, 2026 | Seed Round: $13 million Fortitude Biomedicines launched to advance immune cell-targeting biologics and molecular glue payload-enabled ADCs for autoimmune diseases and cancer, combining immune cell-targeting biologics with a proprietary ADC platform. Its GLUE-DAC(TM) technology involves molecular glue-mediated protein degradation, aiming to overcome resistance, expand target scope, and improve therapeutic efficacy. Date: January 8, 2026 | Series B: $125 million Diagonal Therapeutics is developing a novel class of clustering antibodies designed to correct dysregulated receptor signaling at the root of genetic diseases. This approach induces receptor clustering to restore normal signaling pathways. Its lead program, DIAG723, targets impaired ALK1 signaling in conditions such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Date: January 8, 2026 | Series B: $107 million EpiBiologics to advance pipeline of novel bispecific antibodies to selectively degrade extracellular and membrane-bound disease drivers in oncology and immunology. Their modular EpiTAC system enables precise degradation of pathogenic proteins directly at the disease site. They aim to deliver therapies across oncology and immunology, including mutation-agnostic strategies against targets such as EGFR. Multiple myeloma treatments. Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, leading to impaired hematopoiesis, bone destruction, and organ dysfunction. The disease is driven by genetic and microenvironmental factors that promote tumor cell survival, immune evasion, and resistance to therapy. Despite advances in treatment, multiple myeloma remains largely incurable, with most patients experiencing cycles of response and relapse that require sequential lines of therapy. According to the National Cancer Institute (NCI), there are an estimated 36,110 new cases of multiple myeloma in 2025. The treatment of multiple myeloma has changed significantly over the past decade. Antibody-based modalities have contributed to improved clinical outcomes in pivotal trials, with multiple major pharma players (e.g., Johnson & Johnson, Bristol Myers Squibb, Pfizer) actively competing in this space. Antibodies to watch in Q2 2026. * Bentracimab by SERB Pharmaceuticals: Fab molecule targeting ticagrelor for cardiovascular / hemostasis indications. Currently under US BLA Priority Review, with a PDUFA of Q1 of 2025. * Veligrotug by Viridian Therapeutics, Inc.: mAb targeting IGF-1R for immune-mediated / inflammatory disorder indications. Currently under US, Europe, and Japan review, with a US PDUFA of June 30, 2026. * Apitegromab by Scholar Rock: mAb targeting myostatin for muscular disorder indications. Currently under review in Europe and US, with an EMA decision expected mid-2026, and a PDUFA of September 2026. * Atacicept by Vera Therapeutics, Inc.: Fusion protein targeting BAFF and APRIL for immune-mediated / inflammatory disorder indications. Currently under US BLA Priority Review, with a PDUFA of July 7, 2026. * Garetosmab by Regeneron: mAb targeting activin A protein for genetic disorder indications. Currently under US BLA Priority Review, with a PDUFA of August 2026.
AbbVie presented extensive dermatology data at the American Academy of Dermatology meeting in late March 2026, showcasing long-term outcomes for Skyrizi and Rinvoq. The company shared 24 abstracts, including Phase 3 results for vitiligo and alopecia areata, where upadacitinib is not yet FDA-approved. The FDA recently updated Skyrizi's US prescribing information to include genital and scalp psoriasis data, extending AbbVie's immunology reach into underserved areas. Whilst the new evidence strengthens the clinical foundation for two key immunology products, it does not fundamentally alter AbbVie's investment narrative, which remains heavily dependent on its immunology franchise. AbbVie's narrative projects $77.7 billion revenue and $22.8 billion earnings by 2029, requiring 8.3% annual revenue growth. Analyst fair value estimates range from $249 to $367 per share.